Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Symptomatic infection with COVID-19 confirmed by positive RT-PCR SARS-CoV-2 or, failing that, by thorax CT-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context.~* Diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days.~* Patient having at least one of the following risk factors for developing complications:~  * Age ≥75 years old~ * Age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment~ * Need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (SpO2 \> 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmHg (PaO2/FiO2 ≤ 300 mmHg).~* Patient affiliated to a social security scheme.~* Written and signed consent of the patient or a relative or emergency inclusion procedure.~Exclusion criteria~* Last RT-PCR negative for SARS-CoV-2~* Peripheral capillary oxygen saturation less than or equal to 94% (SpO2 ≤ 94%) despite oxygen therapy greater than or equal to 3 L/min (\> 3 L/min)~* Organ failure requiring admission to a critical or intensive care unit.~* Comorbidity that is life threatening in the short-term (life expectancy \< 3 months)~* Any reason that makes patient follow-up throughout the study impossible~* Current treatment with hydroxychloroquine~* Absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria)~* Hypokalaemia \< 3.5 mmol/L~* Corrected QT prolongation (QTc ≥ 440 ms in men and 460 ms in women).~* Child-Pugh's class C liver cirrhosis~* Chronic kidney failure with estimated GFR ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin~* Women who are pregnant, breastfeeding, or parturient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).